Naringenin Nanoformulations for Neurodegenerative Diseases

Title:Naringenin Nanoformulations for Neurodegenerative Diseases

Volume: 25

Author(s): Liza Sahoo, Nigam Sekhar Tripathy and Fahima Dilnawaz*

Affiliation:

• Department of Biotechnology, School of Engineering and Technology, Centurion University of Technology and Management, Jatni-752050, Bhubaneswar, Odisha, India

Keywords: Glioblastoma, Nanoparticles, Naringenin, Nanoformulations, Flavonoid, Neurodegenerative diseases.

Abstract: Glioblastoma (GBM) is a grade-IV astrocytoma, which is the most common and aggressive type of brain tumor, spreads rapidly and has a life-threatening catastrophic effect. GBM mostly occurs in adults with an average survival time of 15 to 18 months, and the overall mortality rate is 5%. Significant invasion and drug resistance activity cause the poor diagnosis of GBM. Naringenin (NRG) is a plant secondary metabolite byproduct of the flavanone subgroup. NRG can cross the blood-brain barrier and deliver drugs into the central nervous system when conjugated with appropriate nanocarriers and can overcome the challenges associated with gliomas through naringenin-loaded nanoformulations. Here, we discuss several nanocarriers employed as delivery systems, including polymeric nanoparticles, micelles, liposomes, solid lipid nanoparticles (SLNs), nanosuspensions, and nanoemulsions. These naringenin-loaded nanoformulations have been tested in various in vitro and in vivo models and administration routes as a potential treatment for brain disorders. The conclusion from this review is that proper nanoformulations of NRG are a possible therapeutic alternative for the treatment of neurological diseases

Cite this article as:

Sahoo Liza, Tripathy Sekhar Nigam and Dilnawaz Fahima*, Naringenin Nanoformulations for Neurodegenerative Diseases, Current Pharmaceutical Biotechnology 2024; 25 () . https://dx.doi.org/10.2174/0113892010281459240118091137